Cost Analysis With Censored Data
Datos Bibliográficos
| ID | 9101800 |
|---|---|
| Autores | Yijian Huang (0000-0003-4364-3199, Emory University, autor de correspondencia) |
| Año | 2009 |
| Volumen | 47 |
| Número | 7_Supplement_1 |
| Páginas | S115-S119 |
| Fecha de publicación | 2009-07-01 |
| Peer Reviewed | Sí |
| Open Access | No |
| Tipo | ARTICLE |
| Revista | Medical Care (JOURNAL) |
| Identificadores de la revista | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Editorial | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/mlr.0b013e31819bc08a |
| PMID | 19536024 |
| PMCID | PMC2748913 |
| OpenAlex | W2045872322 |
| Idioma | EN |
| Citas recibidas | 5 |
| Referencias citadas | 17 |
Economic evaluation of medical interventions has become an accepted, and often required, adjunct to the standard effectiveness and safety assessment in clinical research. However, the statistical analysis can be challenging due to censored cost data, as commonly obtained in medical studies. Over the past decade, important statistical issues that arise from censored cost data have been identified and a number of advances made to tackle them. In this article, we will describe these issues, including induced dependent censoring and limited identifiability with the cost distribution, and review recent statistical developments. Available methods address either time-restricted medical cost or lifetime medical cost jointly with survival time. Their applicability and limitation in various practical situations will be discussed
Censoring (clinical trials) · Data science · Econometrics · Economics · Identifiability · Machine learning · Risk analysis (engineering) · Computer Science · Health Systems, Economic Evaluations, Quality of Life · Healthcare cost, quality, practices · Healthcare Policy and Management · Medicine
| Obras citantes distintas | 5 |
|---|---|
| Citas por año | 0,29 |
| Intervalo de citas | 2009 - 2009 (1) |
| Velocidad de citación | historical |
| Altamente citado | No |
| Tipos de cita | Neutras: 4 |